Poseida Therapeutics Inc (PSTX)
3.285
-0.06
(-1.79%)
USD |
NASDAQ |
May 20, 12:33
Poseida Therapeutics SG&A Expense (Quarterly): 9.798M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.798M |
| December 31, 2023 | 8.859M |
| September 30, 2023 | 8.092M |
| June 30, 2023 | 8.676M |
| March 31, 2023 | 11.81M |
| December 31, 2022 | 9.368M |
| September 30, 2022 | 9.389M |
| June 30, 2022 | 9.237M |
| March 31, 2022 | 9.546M |
| December 31, 2021 | 9.609M |
| September 30, 2021 | 9.066M |
| Date | Value |
|---|---|
| June 30, 2021 | 8.871M |
| March 31, 2021 | 8.369M |
| December 31, 2020 | 7.476M |
| September 30, 2020 | 6.458M |
| June 30, 2020 | 4.236M |
| March 31, 2020 | 4.854M |
| December 31, 2019 | 4.008M |
| September 30, 2019 | 4.007M |
| June 30, 2019 | 4.042M |
| March 31, 2019 | 6.399M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
4.007M
Minimum
Sep 2019
11.81M
Maximum
Mar 2023
7.788M
Average
8.768M
Median
SG&A Expense (Quarterly) Benchmarks
| Biomea Fusion Inc | 7.283M |
| Cartesian Therapeutics Inc | 9.45M |
| Lantern Pharma Inc | 1.481M |
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |